Immunologic Abnormalities, Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease

Overview

The common causes of mortality are late stages of chronic kidney disease, cardiovascular disease and infections, are associated with abnormalities of the immune system, an underlying state of chronic inflammation and oxidative stress. These processes have not been carefully described in the chronic kidney disease population. The researcher can use Diffuse Optical Spectroscopy to determine the immune system in individuals with chronic kidney disease and describe the association with chronic inflammation and oxidative stress in that population.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: March 2012

Detailed Description

The Diffuse Optical Spectroscopy can measure the absolute concentrations of reduced and oxygenated hemoglobins,cardiac output, mean arterial pressure, blood loss,blood hemoglobin concentration, water and lipid concentrations of the tissue. The researchers can use Diffuse Optical Spectroscopy to monitor volume changes during the hemodialysis treatment and to correlate the changes in volume and blood pressure with the measures of oxidative stress and inflammation used in this study. The researchers can use Diffuse Optical Spectroscopy data to compare to laboratory parameters routinely measured to clinical parameters such as cause of chronic kidney disease, blood pressure and dialysis-related parameters.

Interventions

  • Device: Diffuse Optical Spectroscopy
    • Diffuse Optical Spectroscopy measurements will be compared to a variety of laboratory parameters routinely measured in Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease

Arms, Groups and Cohorts

  • Medical Tool
    • Diffuse Optical Spectroscopy measurements will be compared to a variety of laboratory parameters routinely measured in Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease

Clinical Trial Outcome Measures

Primary Measures

  • Medical Tool
    • Time Frame: 4 weeks
    • Diffuse Optical Spectroscopy measure blood values changes during the hemodialysis treatment.

Participating in This Clinical Trial

Inclusion Criteria

  • 18 years and older with chronic kidney disease undergoing hemodialysis have been treated with hemodialysis for at least 3 months – 18 years and older for control Exclusion Criteria:

  • acute kidney disease

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of California, Irvine
  • Collaborator
    • Beckman Laser Institute University of California Irvine
  • Provider of Information About this Clinical Study
    • Principal Investigator: Beckman Laser Institute and Medical Center, Madeleine Pahl, M.D., Associate Professor of Medicine and Director of the Renal Clinic – University of California, Irvine
  • Overall Official(s)
    • Madeleine Pahl, M.D., Principal Investigator, University of California, Irvine

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.